|
|
News Breaks | | | | January 28, 2013 | | 05:23 EDT |  | SGYP | Synergy Pharmaceuticals begins Phase Ib trial of SP-333
Synergy Pharmaceuticals announced that oral dosing of healthy volunteers has begun in a Phase I clinical trial of SP-333, a guanylate cyclase C, or GC-C, agonist for the treatment of inflammatory bowel disease, IBD, including ulcerative colitis, or UC. SP-333 has exhibited potent anti-inflammatory activity in animal studies of colitis, displaying a novel mechanism-of-action that the company believes could provide a new way to treat UC patients with mild-to-moderate disease. | |
|
News For SGYP From The Last 14 Days Check below for free stories on SGYP the last two weeks. |
|
|
| May 17, 2013 | | 10:36 EDT |  | SGYP | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
 Subscribe for More Information | |
|
|
|
|
|
|
